Table 1.
Clinical trials targeting the tumor-stromal interaction for the treatment of HCC
| Treatment | Phase | Target | Trial ID |
|---|---|---|---|
| Brivanib | 3 | VEGFR2, FGFR1 | NCT00858871 |
| Linifanib | 3 | VEGFR, PDGFR | NCT01009593 |
| Sorafenib | 3 | VEGFR, PDGFR, Raf | NCT00492752 |
| Sunitinib | 3 | VEGFR, PDGFR, c-KIT | NCT00699374 |
| Ramucirumab | 3 | VEGFR2 | NCT01140347 |
| Erlotinib | 3 | EGFR | NCT00901901 |
| PI-88 | 3 | Heparanase, SULFs | NCT00568308 |
| Bevacizumab | 2 | VEGF | NCT00162669 |
| Cediranib | 2 | VEGFR, PDGFR, c-KIT | NCT00238394 |
| BIBF-1120 | 2 | VEGFR, PDGFR, FGFR | NCT01004003 |
| E-7080 | 2 | VEGFR, FGFR, PDGFR, c-KIT | NCT00946153 |
| TSU-68 | 2 | VEGFR2, FGFR, PDGFR | NCT00784290 |
| XL-184 | 2 | VEGFR2, MET, RET | NCT00940225 |
| Vandetanib | 2 | VEGFR, EGFR | NCT00508001 |
| Cetuximab | 2 | EGFR | NCT00142428 |
| BIIB-022 | 2 | IGF-1R | NCT00956436 |
| Cixutumumab | 2 | IGF-1R | NCT00639509 |
| CT-011 | 2 | PD-1/2 | NCT00966251 |
| MEDI-575 | 1 | PDGFR | NCT01102400 |
| BAY73-4506 | 1 | VEGFR, PDGFR, FGFR-1, Raf, RET, c-KIT |
NCT01117623 |
| GC33 | 1 | GPC3 | NCT00976170 |
| AVE1642 | 1 | IGF-1R | NCT00791544 |
| Liver NK cell | 1 | Liver NK cell inoculation | NCT01147380 |